iShares Dow Jones US Real Estate (ETF) (NYSE: IYR)

iShares Dow Jones US Real Estate advanced by 0.23% to close at $52.88. IYR traded 10.12 million shares for the day. Its earning per share remained 19.35. iShares Dow Jones U.S. Real Estate (IYR) is a non-diversified fund. iShares Dow Jones U.S. Real Estate (IYR) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Real Estate Index (the Index). iShares Dow Jones U.S. Real Estate (IYR) measures the performance of the real estate sector of the United States equity market, and includes companies in the industry groups, such as real estate holding and development and real estate investment trusts (REITs). iShares Dow Jones U.S. Real Estate (IYR) invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, iShares Dow Jones U.S. Real Estate (IYR) may or may not hold all of the securities that are included in the Index.

______________________________

iShares S&P 100 Index (ETF) (NYSE: OEF)

iShares S&P 100 Index declined by 0.25% to close at $51.50.OEF traded 2.14 million shares for the day. Its earning per share remained 18.13. iShares S&P 100 Index (OEF) seeks investment results that correspond generally to the price and yield performance of the S&P100 Index (the Index). iShares S&P 100 Index (OEF) measures the performance of the large-capitalization sector of the United States equity market. iShares S&P 100 Index (OEF) is a subset of the S&P 500 and consists of blue chip stocks from diverse industries in the S&P 500 with exchange listed options. iShares S&P 100 Index (OEF) invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, iShares S&P 100 Index (OEF) may or may not hold all of the securities that are included in the Index.

______________________________

POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

Power3 Medical Products, Inc., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

______________________________

iShares Russell 1000 Growth Index (YSE: IWF)

iShares Russell 1000 Growth Index (ETF)declined by 0.43% to close at $51.37.IWF traded 7.13 million shares for the day. Its earning per share remained 17.99. iShares Russell 1000 Growth Index (IWF) seeks investment results that correspond generally to the price and yield performance of the Russell 1000 Growth Index (the Index). iShares Russell 1000 Growth Index (IWF) measures the performance of the large-capitalization growth sector of the United States equity market. The Index is a subset of the Russell 1000 Index. iShares Russell 1000 Growth Index (IWF) is capitalization-weighted, and consists of those companies, or portion of a company, with higher price-to-book ratios and higher forecasted growth within the Russell 1000 Index. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. iShares Russell 1000 Growth Index (IWF) represents approximately 50% of the total market capitalization of the Russell 1000 Index. iShares Russell 1000 Growth Index (IWF) invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index.

*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired.

*******************************************